I82.0 Budd-Chiari syndrome
The ICD-10-CM code for Budd-Chiari syndrome is I82.0 (FY2026). It is a billable, claim-ready diagnosis code.
Classification
- Section
- I80-I89: Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (I80-I89)
- Category I82
- 193 codes (145 billable)
- FY2026 Status
- Stable since FY2024
Also Known As
ICD-10-CM Alphabetic Index entries that lead to I82.0:
- Budd-Chiari syndrome (hepatic vein thrombosis)
- Block, blocked › hepatic vein
- Disease, diseased › Chiari's (hepatic vein thrombosis)
- Syndrome › Budd-Chiari
- Embolism (multiple) (paradoxical) › hepatic (vein)
- Thrombosis, thrombotic (bland) (multiple) (progressive) (silent) (vessel) › hepatic (vein)
- Syndrome › Chiari's (hepatic vein thrombosis)
- Chiari's › disease or syndrome (hepatic vein thrombosis)
Inclusion Terms
- Hepatic vein thrombosis
U.S. Hospital Utilization
- An estimated 3,800 U.S. inpatient stays in 2023 included I82.0 among the documented diagnoses.
- 255 stays listed it as the principal diagnosis.
Source: National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, 2016–2023. National survey-weighted estimates.
Official Coding Guidelines
Presumed relationship due to Index term “with”The classification presumes a causal relationship between hypertension and heart involvement and between hypertension and kidney involvement, as the two conditions are linked by the term “with” in the Alphabetic Index. These conditions should be coded as related even in the absence of provider documentation explicitly linking them, unless the documentation clearly states the conditions are unrelated.
Provider must link conditions not specifically indexed as relatedFor hypertension and conditions not specifically linked by relational terms such as “with,” “associated with” or “due to” in the classification, provider documentation must link the conditions in order to code them as related.
Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026